U.S. Markets closed

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.55-0.29 (-3.28%)
At close: 4:00PM EDT
8.69 +0.14 (1.64%)
After hours: 06:28PM EDT
Sign in to post a message.
  • I
    Investor
  • d
    dcaf7
    Just published: "Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single‑agent selinexor in the SADAL study".
    From the abstract:
    "In a patient population in which survival is expected to be < 6 months, treatment with single-agent oral selinexor was associated with a median survival of 9 months".
  • d
    dcaf7
    A new publication: "Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts"
    Important finding: Monotherapy with Selinexor reduced tumor growth in all KRASmut PDXs, which included 4 different codon mutations, and was more effective than the clinical MEK1/2 inhibitor, Trametinib.
  • M
    MD
    What’s next for this company and stock?
  • d
    dcaf7
    Karyopharm Fights Off Investor Suit on Cancer Drug Trial Results
    July 22, 2021, 5:45 PM

    Karyopharm Therapeutics Inc. is free of accusations it misled investors about the safety and efficacy of its cancer drug selinexor after a federal judge in Massachusetts determined the complaint fell short of alleging wrongdoing.

    The alleged misstatements and omissions about one trial and a study of real-world data aren’t actionable, and the investors didn’t adequately plead that the biopharmaceutical company acted with the required mental state when it omitted information about another trial, the U.S. District Court for the District of Massachusetts said, dismissing the case without prejudice.
  • S
    Snuggler
    I wish KPTI would move forward with KPT-9274. Having read the Nature paper (https://www.nature.com/articles/srep42555) and worked with the compound itself in-vitro on liver cancer cell lines, it has the potential to be a major breakthrough as a chemotherapeutic agent to target aggressive cancers types and prevent metastasizing. Of course Xpov and their next drug in the pipeline are first in class as well. I initially sold when I tripled my money once the finally approved Xpovio and the stock went up to $16 roughly but I will be buying back in again for the long haul.
    Breast cancer is a heterogeneous disease consisting of several subtypes. Among these subtypes, triple negative breast cancer is particularly difficult to treat. This is due to a lack of understanding of the mechanisms behind the disease, and conseque
    Breast cancer is a heterogeneous disease consisting of several subtypes. Among these subtypes, triple negative breast cancer is particularly difficult to treat. This is due to a lack of understanding of the mechanisms behind the disease, and conseque
    www.nature.com
    Bullish
  • J
    JJ
    KPTI has a 22.74% short interest. This puts it in the top 30 of most heavily shorted stocks. It has a price under $10 and market value of less than $800 million. This is the perfect stock for the reddit group and wallstreetbets to push higher. It also has approved drugs that have potential sales of $700 million in 2-3 years. Please get the word out so that we can remove the hold that shorts have on this stock.
  • I
    InvestmentFreak
    This is one of the most shorted Biotech stocks. Let’s squeeze the shorts out of KPTI!
    Bullish
  • K
    Keith
    Finally a bullish chart for KPTI. A saucer pattern is developing very nicely.
  • d
    dcaf7
    From Jefferies presentation:
    In Covid environment, Xpovio is the only product in MM that demonstrated growth. The other products were flat or negative.
  • S
    Spark
    KPTI receives 100 million from HCR. That's how you run a biotech and look after share value.
  • M
    MD
    WTH is going on with this, WHATTT
  • K
    Ken
    Nice movement today. I loaded up a bunch over the past few days. Ready for the journey to that $49 target!
  • I
    InvestmentFreak
    KPTI seems to be ridiculously undervalued. Bought a sizeable position over the last few weeks and think about adding to my position after today’s bullish news!
    Bullish
  • G
    German Curry Sausage
    Preliminary approval granted in the UK. Well, now! Normally the price would have to jump up like at AMC in the last few days, but the shortsellers still have the reins in their hands. However, I do not want to miss the wave to the top for any price in the world, which will reach epic proportions if the positions have to be closed.
    Bullish
  • M
    Marc
    This stocks history will repeat . Be patient..they will go up it may take some time. I'd stock up now at the current price. Big institutions are holding the bag for a reason and so am I.
    Bullish
  • G
    German Curry Sausage
    10 analysts give a median price target of USD 24.70 Wake-up call Karyopharm, what are we waiting for here? I'm ready to go.
    Neutral
  • C
    Chi Yin Gabriel
    Time for every bull to write to the KPTI Board to stop the insider selling! The latest is Stephen Mitchener sold on June 3rd, and the stock tanked 3.14% the next day! The ex-CEO and ex-president had driven the stock price to the ground by their selfish selling triggered short selling. KPTI is now one of the most shorted stock! STOP THESE BS INSIDER SELLING! Time for the Board to defend the interest of the share holders!
    Bullish
  • S
    Spark
    organizational changes at KPTI just announced.
  • J
    JJ
    https://wsw.com/webcast/jeff174/kpti/1866024
    Use this link to view the latest KPTI information with new CEO. Very informative.